The health assessment software provider secured the funding in a series B round led by Bayer that also featured Samsung Catalyst Fund.
Chemicals and pharmaceutical group Bayer has led a $90m series B round for Germany-based healthcare intelligence technology provider Ada Health through its corporate venture capital subsidiary, Leaps by Bayer.
Consumer electronics manufacturer Samsung also took part in the round, through its Samsung Catalyst Fund, investing together with financial services firm Inteligo Bank, Vitruvian Partners, F4 and Mutschler Ventures.
Ada has created health assessment technology which uses artificial intelligence to help users assess their health through logging their symptoms and then…
